Bank Amer (BAC) Stock Value Declined While Clough Capital Partners LP Has Raised Holding; As Vertex Pharmaceuticals (VRTX) Stock Rose, Holder Perceptive Advisors Has Cut Stake

January 19, 2018 - By Henry Gaston

Charles Clough increased its stake in Bank Amer Corp (BAC) by 4.26% based on its latest 2017Q3 regulatory filing with the SEC. Clough Capital Partners LP bought 102,800 shares as the company’s stock declined 6.00% while stock markets rallied. The hedge fund run by Charles Clough held 2.51 million shares of the major banks company at the end of 2017Q3, valued at $63.71M, up from 2.41 million at the end of the previous reported quarter. Clough Capital Partners LP who had been investing in Bank Amer Corp for a number of months, seems to be bullish on the $330.75B market cap company. The stock increased 0.73% or $0.23 during the last trading session, reaching $31.71. About 52.80M shares traded. Bank of America Corporation (NYSE:BAC) has risen 58.64% since January 19, 2017 and is uptrending. It has outperformed by 41.94% the S&P500.

Joseph Edelman decreased its stake in Vertex Pharmaceuticals Inc (VRTX) by 50.02% based on its latest 2017Q3 regulatory filing with the SEC. Perceptive Advisors Llc sold 138,726 shares as the company’s stock rose 33.61% with the market. The hedge fund run by Joseph Edelman held 138,626 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $21.08 million, down from 277,352 at the end of the previous reported quarter. Perceptive Advisors Llc who had been investing in Vertex Pharmaceuticals Inc for a number of months, seems to be less bullish one the $40.00 billion market cap company. The stock increased 0.62% or $0.98 during the last trading session, reaching $158.17. About 1.49 million shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since January 19, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on January, 24. They expect $0.28 earnings per share, up 115.38% or $0.15 from last year’s $0.13 per share. VRTX’s profit will be $70.81M for 141.22 P/E if the $0.28 EPS becomes a reality. After $0.24 actual earnings per share reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts 16.67% EPS growth.

Investors sentiment increased to 1.62 in Q3 2017. Its up 0.11, from 1.51 in 2017Q2. It increased, as 32 investors sold VRTX shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Moore Capital Mngmt Ltd Partnership invested in 25,000 shares. Geode Capital Limited Liability Company holds 0.14% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2.50 million shares. Pacad Ltd holds 0.09% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2,600 shares. Pnc Fincl Ser Group Incorporated holds 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 25,905 shares. Advantus Capital reported 25,555 shares stake. Fred Alger Mgmt reported 1.73M shares. Retail Bank Of Ny Mellon invested 0.08% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 4,850 are held by Endurance Wealth Management Inc. First Citizens State Bank & Tru holds 0.05% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 2,720 shares. Legal And General Public Limited Co has invested 0.13% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Arrow Financial holds 0.01% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 300 shares. Oppenheimer has 4,445 shares for 0.02% of their portfolio. Renaissance Techs Lc, a New York-based fund reported 1.37M shares. Axa has 0.18% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Moreover, Price T Rowe Associate Inc Md has 0.69% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Since July 31, 2017, it had 0 buys, and 30 selling transactions for $90.79 million activity. Another trade for 5,390 shares valued at $830,960 was sold by Chodakewitz Jeffrey. 777 shares valued at $116,511 were sold by Graney Thomas on Tuesday, January 2. $334,232 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by SMITH IAN F. Parini Michael had sold 2,125 shares worth $324,976 on Thursday, October 12. The insider Arbuckle Stuart A sold 4,250 shares worth $675,750. Another trade for 56,250 shares valued at $8.83M was sold by ALTSHULER DAVID.

Perceptive Advisors Llc, which manages about $2.09 billion and $2.62 billion US Long portfolio, upped its stake in Capital Sr Living Corp (NYSE:CSU) by 30,000 shares to 560,173 shares, valued at $7.03M in 2017Q3, according to the filing. It also increased its holding in Avadel Pharmaceuticals Plc by 119,891 shares in the quarter, for a total of 1.55M shares, and has risen its stake in Acceleron Pharma Inc (NASDAQ:XLRN).

Among 28 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 24 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. Vertex Pharmaceuticals had 81 analyst reports since July 31, 2015 according to SRatingsIntel. On Thursday, October 26 the stock rating was maintained by Piper Jaffray with “Buy”. BMO Capital Markets maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Tuesday, July 18. BMO Capital Markets has “Buy” rating and $18000 target. On Monday, September 25 the stock rating was maintained by Jefferies with “Buy”. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Thursday, July 27 by Oppenheimer. Vetr upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Tuesday, September 1. Vetr has “Buy” rating and $143.70 target. The rating was maintained by JMP Securities on Tuesday, December 12 with “Buy”. The rating was maintained by Leerink Swann on Tuesday, September 26 with “Buy”. The firm earned “Outperform” rating on Wednesday, July 19 by Cowen & Co. The rating was maintained by Maxim Group with “Buy” on Wednesday, July 19. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Monday, September 25 by BMO Capital Markets.

Among 32 analysts covering Bank of America (NYSE:BAC), 21 have Buy rating, 0 Sell and 11 Hold. Therefore 66% are positive. Bank of America had 104 analyst reports since July 21, 2015 according to SRatingsIntel. Keefe Bruyette & Woods downgraded it to “Market Perform” rating and $16 target in Monday, May 16 report. Macquarie Research upgraded Bank of America Corporation (NYSE:BAC) on Tuesday, September 1 to “Hold” rating. On Tuesday, January 2 the stock rating was maintained by Robert W. Baird with “Hold”. The stock of Bank of America Corporation (NYSE:BAC) earned “Buy” rating by Credit Suisse on Thursday, June 1. The company was maintained on Friday, August 11 by Jefferies. The company was maintained on Tuesday, July 21 by Jefferies. Keefe Bruyette & Woods maintained it with “Buy” rating and $2700 target in Tuesday, June 6 report. The firm has “Outperform” rating by CLSA given on Friday, September 23. Nomura maintained it with “Buy” rating and $30 target in Monday, October 16 report. The stock of Bank of America Corporation (NYSE:BAC) earned “Buy” rating by Deutsche Bank on Tuesday, January 26.

Since August 10, 2017, it had 0 insider purchases, and 1 sale for $2.10 million activity.

Clough Capital Partners L P, which manages about $5.01B and $1.49 billion US Long portfolio, decreased its stake in Imax Corp (NYSE:IMAX) by 184,021 shares to 15,860 shares, valued at $359,000 in 2017Q3, according to the filing. It also reduced its holding in Ishares Tr (INDA) by 23,300 shares in the quarter, leaving it with 69,900 shares, and cut its stake in Golub Cap Bdc Inc (NASDAQ:GBDC).

Investors sentiment decreased to 1.04 in 2017 Q3. Its down 0.08, from 1.12 in 2017Q2. It worsened, as 68 investors sold BAC shares while 569 reduced holdings. 117 funds opened positions while 547 raised stakes. 6.91 billion shares or 9.01% more from 6.34 billion shares in 2017Q2 were reported. Mechanics Natl Bank Trust Department invested 0.08% of its portfolio in Bank of America Corporation (NYSE:BAC). Doheny Asset Mgmt Ca accumulated 102,380 shares. Greenwich Wealth Mngmt Lc holds 134,110 shares. Toscafund Asset Mgmt Ltd Liability Partnership stated it has 18.35% in Bank of America Corporation (NYSE:BAC). Philadelphia Tru Com stated it has 981,914 shares or 2.04% of all its holdings. Montag A Assoc stated it has 0.67% in Bank of America Corporation (NYSE:BAC). Causeway Mngmt Lc has invested 1.63% in Bank of America Corporation (NYSE:BAC). Caxton LP stated it has 1.94% in Bank of America Corporation (NYSE:BAC). Baker Ellis Asset Mngmt Limited Liability Corp invested in 0.1% or 14,600 shares. Birmingham Management Al invested in 91,470 shares or 0.92% of the stock. Fishman Jay A Mi owns 112,371 shares for 0.58% of their portfolio. Rbf Cap Ltd Liability reported 2.68% in Bank of America Corporation (NYSE:BAC). Pathstone Family Office Ltd Liability Company holds 0.01% or 500 shares. Aureus Asset Mgmt Limited owns 10,798 shares for 0.04% of their portfolio. Fisher Asset Ltd Liability has invested 0.58% in Bank of America Corporation (NYSE:BAC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts